Dr. Reddy's Laboratories Ltd. (RDY)

37.73
0.59 1.50
NYSE : Health Technology
Prev Close 38.32
Open 38.01
Day Low/High 37.70 / 38.04
52 Wk Low/High 29.00 / 42.82
Volume 68.97K
Avg Volume 158.00K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 6.43B
EPS 1.60
P/E Ratio 23.45
Div & Yield 0.29 (0.71%)
Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong on high relative volume candidate

If a Market Crash Is Coming, Here's What to Do With Your Stocks, Bonds and Mutual Funds

If a Market Crash Is Coming, Here's What to Do With Your Stocks, Bonds and Mutual Funds

U.S. markets seem to be running out of steam. If markets crash, here are the criteria to check when deciding whether to sell a stock, mutual fund or bond.

Dr Reddy Laboratories (RDY) Weak On High Volume

Dr Reddy Laboratories (RDY) Weak On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a weak on high relative volume candidate

Statement From Dr. Reddy's Regarding The Receipt Of Temporary Restraining Order (TRO) For Esomeprazole Capsules

Statement From Dr. Reddy's Regarding The Receipt Of Temporary Restraining Order (TRO) For Esomeprazole Capsules

Dr. Reddy's Laboratories (NYSE: RDY) in a statement issued today said that it has been made aware of an order passed by the District Court of Delaware, USA, granting a Temporary Restraining Order (TRO) with immediate effect...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Dr. Reddy's Laboratories Ltd. - RDY

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Dr. Reddy's Laboratories Ltd. - RDY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dr.

Dr. Reddy's To Hold A Conference Call On Nov 9, 2015 At 4.00 PM IST / 5.30 AM EST

Dr. Reddy's To Hold A Conference Call On Nov 9, 2015 At 4.00 PM IST / 5.30 AM EST

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will hold a Conference Call on November 9, 2015 to clarify investors' queries on the Warning Letter issued by the US FDA dated November 05, 2015.

5 Toxic Stocks to Sell Now

5 Toxic Stocks to Sell Now

Here's a technical look at five stocks you need to unload from your portfolio in November.

Dr. Reddy's Statement On The Receipt Of Warning Letter From US FDA

Dr. Reddy's Statement On The Receipt Of Warning Letter From US FDA

Dr. Reddy's Laboratories (BSE: 500124) (NYSE: RDY) today issued a statement acknowledging that it has received a warning letter issued by the US FDA dated November 05, 2015 relating to its API manufacturing facilities...

Biocodex Inks Distribution Pact With Dr. Reddy's To Market Its Flagship Products In Romania

Biocodex Inks Distribution Pact With Dr. Reddy's To Market Its Flagship Products In Romania

Dr. Reddy's Laboratories (NYSE: RDY) has entered into a strategic alliance with Biocodex to market and distribute Biocodex products in the Romanian market.

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr. Reddy's Strengthens OTC Portfolio - Launches Nise D Spray

Dr. Reddy's Strengthens OTC Portfolio - Launches Nise D Spray

Dr. Reddy's today announced the launch of Nise D Spray, emphasizing its strategic intent of being a player of substance in the Indian OTC (Over The Counter) space.

Dr. Reddy's Q2 And H1 FY16 Financial Results

Dr. Reddy's Q2 And H1 FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q2FY16 Results On Oct 29, 2015 // Earnings Call Slated For Oct 29, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q2FY16 Results On Oct 29, 2015 // Earnings Call Slated For Oct 29, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half year ended September 30, 2015 on Thursday, October 29, 2015 after the Board Meeting.

Dr Reddy Laboratories (RDY) Showing Signs Of Being Strong And Under The Radar

Dr Reddy Laboratories (RDY) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr. Reddy's Announces The Launch Of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 Mg And 40 Mg

Dr. Reddy's Announces The Launch Of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 Mg And 40 Mg

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM ® (esomeprazole...

Dr. Reddy's Laboratories Signs Commercialization Deal With Hatchtech

Dr. Reddy's Laboratories Signs Commercialization Deal With Hatchtech

Dr. Reddy's Laboratories (NYSE: RDY) today announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™...

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx, Inc., a global medical nutrition company based in Boulder, Colorado, and Dr.

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx And Dr. Reddy's Announce An Agreement To Market PanTheryx's Proprietary Nutritional Intervention For Pediatric Infectious Diarrhea

PanTheryx, Inc., a global medical nutrition company based in Boulder, Colorado, and Dr.

Today's Weak On High Volume Stock: Dr Reddy Laboratories (RDY)

Today's Weak On High Volume Stock: Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a weak on high relative volume candidate

Dr. Reddy's Announces Management Changes

Dr. Reddy's Announces Management Changes

Dr. Reddy's Laboratories (NYSE: RDY) today announced the following senior level changes in their global management structure.

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr. Reddy's Announces The Launch Of PRAMIPEXOLE Dihydrochloride Extended-Release Tablets

Dr. Reddy's Announces The Launch Of PRAMIPEXOLE Dihydrochloride Extended-Release Tablets

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.

Dr. Reddy's Announces Strategic Collaboration With Amgen In India

Dr. Reddy's Announces Strategic Collaboration With Amgen In India

Dr. Reddy's Laboratories Ltd.

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Dr Reddy Laboratories (RDY) Is Today's Strong And Under The Radar Stock

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

New Lifetime High For Dr Reddy Laboratories (RDY)

New Lifetime High For Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Q1 FY16 Financial Results

Dr. Reddy's Q1 FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

TheStreet Quant Rating: C (Hold)